Dopamine News and Research

Latest Dopamine News and Research

Drug prescribed for Parkinson's disease may also treat restless leg syndrome: MCG researchers

A drug prescribed for Parkinson's disease may also treat restless leg syndrome without the adverse side effects of current therapies, Medical College of Georgia researchers say.

7 Dec 2010

Genes linked to one-night stands and acts of infidelity

So, he or she has cheated on you for the umpteenth time and their only excuse is: "I just can't help it." According to researchers at Binghamton University, they may be right. The propensity for infidelity could very well be in their DNA.

1 Dec 2010

Clinicians should assess sleep-wake disturbances to understand physiology of Parkinson's disease

Nearly three-quarters of patients with Parkinson's disease experience fatigue or excessive daytime sleepiness (EDS), but clinicians should assess both problems separately in order to improve the profession's understanding of their distinct, but overlapping, physiology. That is the key finding of a study published in the December issue of the European Journal of Neurology.

1 Dec 2010

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Neuroscientists using a new brain imaging technique could see an investigational drug for Parkinson's disease get into a patient's brain and affect blood flow in several key structures, an indicator the drug may be effective.

1 Dec 2010

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.

30 Nov 2010

CAMH neuroscientists develop novel protein peptide for targeted treatment of depression

Neuroscientists at the Centre for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.

30 Nov 2010

XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies

XenoPort, Inc. announced today that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research to support a preclinical study of the efficacy and safety of a novel, orally administered prodrug of acamprosate in reducing L-Dopa induced dyskinesias (LID) in a pre-clinical model of Parkinson's disease.

24 Nov 2010

Parkinson Society Canada awards Quebec scientists $573,384 for research

Quebec Parkinson researchers receive a record $573,384 in funding from Parkinson Society Canada to increase their efforts to identify the causes of this degenerative brain disease for which there is currently no cure. At a Research Innovation event in Montreal this evening, hosted by Parkinson Society Quebec in partnership with McGill University and the CHUM, 11 Parkinson scientists will be lauded for their efforts in getting closer to a cure.

23 Nov 2010

Scientists solve receptor structure that responds to neurotransmitter dopamine

A team led by scientists at The Scripps Research Institute has solved the structure of one of the receptors that responds to the neurotransmitter dopamine. Although dopamine transmission is essential to normal brain functioning, the biological assembly of the molecules involved in this crucial neuronal interplay had not been known until now.

19 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Neurologix third quarter net loss decreases to $2.3 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system ("CNS"), today reported its financial results for the three and nine months ended September 30, 2010.

12 Nov 2010

Exhausted neurons die prematurely and trigger disease symptoms

We all know that living a stressful lifestyle can take its toll, making us age faster and making us more susceptible to the cold going around the office.

11 Nov 2010

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

Nabi Biopharmaceuticals announced today that it has completed enrollment in the second Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational candidate vaccine being developed to treat nicotine addiction and prevent smoking relapse.

10 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.

1 Nov 2010

New computational techniques to overcome obstacles in hard-to-study genes

Scientists have invented methods to scout the human genome's repetitive landscapes, where DNA sequences are highly identical and heavily duplicated. These advances, as reported today in Science, can identify subtle but important differences among people in the number and content of repeated DNA segments.

28 Oct 2010

Tel Aviv University research links obsessive-compulsive disorder to common childhood illness

A common infection in children, strep throat can lead to problems with a child's heart, joints or brain if left untreated. And when the brain is involved, motor and mental functioning may be compromised, leading to syndromes such as attention deficit disorder and obsessive-compulsive disorder (OCD).

21 Oct 2010

Dopamine vital for rhythmic expression in specific brain regions: Research

Daily sleeping and eating patterns are critical to human well-being and health. Now, a new study from Concordia University has demonstrated how the brain chemical dopamine regulates these cycles by altering the activity of the "clock-protein" PER2. Published in the Journal of Neuroscience, these findings may have implications for individuals with Parkinson's Disease with disrupted 24-hour rhythms of activity and sleep.

21 Oct 2010

Study finds different activity patterns of genes in brain of individuals with different genetic backgrounds

Researchers at the Allen Institute for Brain Science have found that the same genes have different activity patterns in the brain in individuals with different genetic backgrounds. These findings may help to explain individual differences in the effectiveness and side-effect profiles of therapeutic drugs and thus have implications for personalized medicine. The study is available in this week's online early edition of the Proceedings of the National Academy of Sciences (www.pnas.org).

20 Oct 2010

Dopamine News and Research

Latest Dopamine News and Research

Drug prescribed for Parkinson's disease may also treat restless leg syndrome: MCG researchers

Genes linked to one-night stands and acts of infidelity

Clinicians should assess sleep-wake disturbances to understand physiology of Parkinson's disease

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

CAMH neuroscientists develop novel protein peptide for targeted treatment of depression

XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies

Parkinson Society Canada awards Quebec scientists $573,384 for research

Scientists solve receptor structure that responds to neurotransmitter dopamine

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Neurologix third quarter net loss decreases to $2.3 million

Exhausted neurons die prematurely and trigger disease symptoms

Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction

Phase III study suggests CYCLOSET tablets improve glycemic control

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

New computational techniques to overcome obstacles in hard-to-study genes

Tel Aviv University research links obsessive-compulsive disorder to common childhood illness

Dopamine vital for rhythmic expression in specific brain regions: Research

Study finds different activity patterns of genes in brain of individuals with different genetic backgrounds

Quality, Patient Safety and Innovation Manager at Elsevier

How Bruker worked with the University of Manchester on mapping the dynamics of complex protein

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Dopamine News and Research

Latest Dopamine News and Research

Quality, Patient Safety and Innovation Manager at Elsevier

How Bruker worked with the University of Manchester on mapping the dynamics of complex protein

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Newsletters you may be interested in